TRACON Pharmaceuticals, Inc.
Other OTCCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Craig R. Jalbert CIRA
- Full Time Employees
- 17
- Sector
- Healthcare
- Industry
- Biotechnology
- Address
- 4350 La Jolla Village Drive San Diego CA United States of America 92122
- IPO Date
- Jan 30, 2015
- CIK
- 0001394319
- Website
- traconpharma.com
- Similar Companies
- Business
- TRACON Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics primarily for cancer and fibrotic diseases in the United States. Its main product candidates include envafolimab (KN035), a PD-L1 single-domain antibody for the treatment of refractory soft tissue sarcoma; YH001, an investigational humanized cytotoxic T-lymphocyte-associated protein 4 (CTLA-4) IgG1 monoclonal antibody in Phase I clinical trials for various cancer indications; TRC102, a small molecule in Phase II clinical development aimed at reversing resistance to specific chemotherapeutics by inhibiting DNA base excision repair, being tested for mesothelioma, lung cancer, glioblastoma, and solid tumors; and TJ004309, a CD73 antibody in Phase I clinical development for treating solid tumors. The company also operates a contract research organization (CRO) independent product development platform to partner with other life science companies for product development and commercialization. Founded in 2006 and headquartered in San Diego, California, TRACON recently announced a major operational shift as it initiated a wind-down of its operations in mid-2024. This process involved terminating all employees and significant leadership changes, including the appointment of Craig R. Jalbert as the new CEO, President, Treasurer, Secretary, and sole board member. The company is moving towards dissolution and liquidation pending stockholder consent. Prior to this, in early 2024, TRACON executed a reverse stock split to consolidate its shares. These moves signal a strategic wind-down of its business activities despite its ongoing clinical pipeline and partnership platform. The company’s focus on targeted therapies within oncology and fibrotic disease segments reflects its industry niche, aiming to address unmet medical needs through precision biologics and small molecule drugs. TRACON engages predominantly in the United States market through its clinical-stage drug developments and strategic product partnerships, leveraging both internal programs and collaborations. Its portfolio of investigational therapies includes immune checkpoint inhibitors and resistance-modulating agents designed to advance cancer treatment options. TRACON Pharmaceuticals stands as a niche clinical-stage entity with specialized assets in immuno-oncology and DNA repair inhibition, but recent decisions to cease operations mark a significant transition from active development toward corporate wind-down and shareholder value realization. The company’s research-driven approach and platform capabilities underpin its prior and ongoing attempts at therapeutic innovation in highly competitive oncology segments.
TRACON Pharmaceuticals Announces it Will Wind Down Operations
TRACON Announces Publication in Clinical Cancer Research of Phase 2 Clinical Data for TRC102, a DNA Damage Repair Inhibitor, in Recurrent Glioblastoma Patients
TRACON Pharmaceuticals, Inc. (TCON) Q1 2024 Earnings Call Transcript
TRACON Pharmaceuticals Reports First Quarter 2024 Financial Results and Provides Corporate Update
TRACON to Report First Quarter 2024 Financial Results and Provide Corporate Update on May 14, 2024
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for April 2024
TRACON Pharmaceuticals Announces Reverse Stock Split
TRACON Pharmaceuticals, Inc. (TCON) Q4 2023 Earnings Call Transcript
TRACON Pharmaceuticals Reports Fourth Quarter and Year-End 2023 Financial Results and Provides Corporate Update
TRACON to Report Fourth Quarter and Year-End 2023 Financial Results and Provide Corporate Update on March 5, 2024
TRACON Pharmaceuticals Provides Positive Update on Ongoing ENVASARC Pivotal Phase 2 Trial
Why Is Tracon Pharmaceuticals (TCON) Stock Up 19% Today?
TRACON Pharmaceuticals Announces License of Product Development Platform for $3.0 Million Upfront Payment
Why Is Tracon Pharmaceuticals (TCON) Stock Down 22% Today?
Why Is Tracon Pharmaceuticals (TCON) Stock Up 130% Today?
TRACON Pharmaceuticals, Inc. (TCON) Q3 2023 Earnings Call Transcript
TRACON Pharmaceuticals Reports Third Quarter 2023 Financial Results and Provides Corporate Update
TRACON to Report Third Quarter 2023 Financial Results and Provide Corporate Update on November 9, 2023
TRACON Pharmaceuticals Announces ENVASARC Phase 2 Pivotal Trial Exceeded Futility Threshold at Final Interim Analysis and Will Continue as Planned
TRACON Pharmaceuticals Announces Participation at Upcoming Investor Conferences